FR2358881B1 - - Google Patents

Info

Publication number
FR2358881B1
FR2358881B1 FR7622045A FR7622045A FR2358881B1 FR 2358881 B1 FR2358881 B1 FR 2358881B1 FR 7622045 A FR7622045 A FR 7622045A FR 7622045 A FR7622045 A FR 7622045A FR 2358881 B1 FR2358881 B1 FR 2358881B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7622045A
Other languages
French (fr)
Other versions
FR2358881A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Priority to FR7622045A priority Critical patent/FR2358881A1/fr
Priority to NZ184666A priority patent/NZ184666A/xx
Priority to IL52550A priority patent/IL52550A/xx
Priority to IE1509/77A priority patent/IE45454B1/en
Priority to SE7708349A priority patent/SE7708349L/
Priority to AU27151/77A priority patent/AU508753B2/en
Priority to GB30355/77A priority patent/GB1556567A/en
Priority to DE19772732614 priority patent/DE2732614A1/de
Priority to CA283,049A priority patent/CA1077846A/en
Priority to BE179459A priority patent/BE856937A/xx
Priority to LU77796A priority patent/LU77796A1/xx
Priority to ZA00774376A priority patent/ZA774376B/xx
Priority to NL7708055A priority patent/NL7708055A/xx
Priority to JP8785277A priority patent/JPS5326327A/ja
Publication of FR2358881A1 publication Critical patent/FR2358881A1/fr
Application granted granted Critical
Publication of FR2358881B1 publication Critical patent/FR2358881B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR7622045A 1976-07-20 1976-07-20 Composition pharmaceutique active sur le systeme nerveux central Granted FR2358881A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR7622045A FR2358881A1 (fr) 1976-07-20 1976-07-20 Composition pharmaceutique active sur le systeme nerveux central
IL52550A IL52550A (en) 1976-07-20 1977-07-18 Pharmaceutical compositions having an action on the central nervous system coprising a gabamimetic compound and a neuroleptic compound
NZ184666A NZ184666A (en) 1976-07-20 1977-07-18 Pharmaceutical compositions comprising a gabamimetic compound and a neuroleptic compound
DE19772732614 DE2732614A1 (de) 1976-07-20 1977-07-19 Arzneimittel mit wirkung auf das zentralnervensystem
AU27151/77A AU508753B2 (en) 1976-07-20 1977-07-19 Central nervous system pharmaceuticals
GB30355/77A GB1556567A (en) 1976-07-20 1977-07-19 Pharmaceutical compositions having an action on the central nervous system
IE1509/77A IE45454B1 (en) 1976-07-20 1977-07-19 Pharmaceutical compositions having an action on the central nervous system
CA283,049A CA1077846A (en) 1976-07-20 1977-07-19 Pharmaceutical compositions having an action on the central nervous system
BE179459A BE856937A (fr) 1976-07-20 1977-07-19 Compositions pharmaceutiques actives sur le systeme nerveux central
LU77796A LU77796A1 (enExample) 1976-07-20 1977-07-19
SE7708349A SE7708349L (sv) 1976-07-20 1977-07-19 Farmaceutiska kompositioner och forfarande for framstellning derav
NL7708055A NL7708055A (nl) 1976-07-20 1977-07-20 Werkwijze voor het bereiden van een geneesmid- del en zo gevormd geneesmiddel.
ZA00774376A ZA774376B (en) 1976-07-20 1977-07-20 Pharmaceutical compositions having an action on the central nervous system
JP8785277A JPS5326327A (en) 1976-07-20 1977-07-20 Medical composition active to central nerve system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7622045A FR2358881A1 (fr) 1976-07-20 1976-07-20 Composition pharmaceutique active sur le systeme nerveux central

Publications (2)

Publication Number Publication Date
FR2358881A1 FR2358881A1 (fr) 1978-02-17
FR2358881B1 true FR2358881B1 (enExample) 1980-10-03

Family

ID=9175888

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7622045A Granted FR2358881A1 (fr) 1976-07-20 1976-07-20 Composition pharmaceutique active sur le systeme nerveux central

Country Status (3)

Country Link
BE (1) BE856937A (enExample)
FR (1) FR2358881A1 (enExample)
ZA (1) ZA774376B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231099A (en) * 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs

Also Published As

Publication number Publication date
BE856937A (fr) 1978-01-19
ZA774376B (en) 1978-06-28
FR2358881A1 (fr) 1978-02-17

Similar Documents

Publication Publication Date Title
FR2360046B2 (enExample)
JPS5626139B2 (enExample)
JPS5440419Y2 (enExample)
JPS555762B2 (enExample)
JPS52129254U (enExample)
JPS5289421U (enExample)
JPS5515939Y2 (enExample)
JPS5438444Y2 (enExample)
JPS5553056Y2 (enExample)
JPS5727626Y2 (enExample)
JPS52159030U (enExample)
JPS5362221U (enExample)
CS178373B1 (enExample)
JPS5376848U (enExample)
JPS52136373U (enExample)
JPS52140648U (enExample)
CS175524B1 (enExample)
DD126062A1 (enExample)
DD124331A1 (enExample)
DD125807A1 (enExample)
CH597981A5 (enExample)
DD125705A2 (enExample)
BG23440A1 (enExample)
DD125663A1 (enExample)
CH613307A5 (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse